New Insights into Cancer Vaccines and Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (31 January 2020) | Viewed by 113593
Special Issue Editor
Interests: drug discovery in the ubiquitin-proteasome; antibody therapeutics; mass spectrometry and proteomics; interferon signaling in cancer
Special Issue Information
Dear Colleagues,
Immune-based therapies are powerful tools in the fight against cancer. The similarities in canine and human cancer genetics and therapeutic responses have promoted comparative oncology as an important research area for developing better treatments for animal and human disease. New technical developments in genomics and proteomics paired with the fervent climate of modern data science bioinformatics have made comparative oncology a cutting-edge field when it comes to understanding genetic and epigenetic causes of cancer. This Special Issue is focused on recent advancements in the discovery of immune-based therapies and how comparative oncology will lead to a better understanding of how the immune system can be harnessed for personalized and preventative medicines.
Prof. Ted Hupp
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- comparative oncology
- immune therapy
- neoantigens
- cancer vaccines
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.